Drugs / Scopoderm
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03616067 Comparator | Apr 2022 → Sep 2025 | cerebral palsy | Hospices Civils de Lyon | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Scopoderm | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03616067 ↗ |
| Known as | scopolamine | “The hypothesis is that therapeutic treatment of drooling in children with cerebral palsy consisting of a standardized rehabilitation treatment associated with a botulinum toxin...” NCT03616067 ↗ |
| Route | Topical | “Scopoderm® patches will be initiated one month after inclusion” NCT03616067 ↗ |